Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study.
Shehab M, Alali A, Al-Hindawi A, Alsayegh A, Aldallal U, Abdullah I, Albaghli A, Alrashed F, Alfadhli A, Bessissow T. Shehab M, et al. Among authors: alfadhli a. Front Med (Lausanne). 2023 Jan 6;9:1045661. doi: 10.3389/fmed.2022.1045661. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36687448 Free PMC article.
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
Shehab M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Mohammad H, Cherian P, Al-Khairi I, Alphonse Thanaraj T, Channanath A, Ali H, Abu-Farha M, Abubaker J, Al-Mulla F. Shehab M, et al. Among authors: alfadhli a. Vaccines (Basel). 2021 Dec 13;9(12):1471. doi: 10.3390/vaccines9121471. Vaccines (Basel). 2021. PMID: 34960217 Free PMC article.
Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study.
Shehab M, Alasfour H, Abdullah I, Alhendi G, Alhadab A, Alfadhli A, Ziyab AH, Battat R. Shehab M, et al. Among authors: alfadhli a. Front Med (Lausanne). 2021 Dec 23;8:801532. doi: 10.3389/fmed.2021.801532. eCollection 2021. Front Med (Lausanne). 2021. PMID: 35004778 Free PMC article.
Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.
Shehab M, Alrashed F, Abdullah I, Alfadhli A, Ali H, Abu-Farha M, Channanath AM, Abubaker JA, Al-Mulla F. Shehab M, et al. Among authors: alfadhli a. Front Med (Lausanne). 2022 Jun 8;9:881027. doi: 10.3389/fmed.2022.881027. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35755075 Free PMC article.
Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M, Alrashed F, Alfadhli A, Alsayegh A, Aldallal U, Alsayegh M, Cherian P, Alkhair I, Thanaraj TA, Channanath A, Dashti AA, Albanaw A, Ali H, Abu-Farha M, Abubaker J, Al-Mulla F. Shehab M, et al. Among authors: alfadhli a. Front Med (Lausanne). 2022 Jul 4;9:933996. doi: 10.3389/fmed.2022.933996. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35860742 Free PMC article.
69 results